Ocular Therapeutix (OCUL) Stock Statistics & Valuation Metrics

Ocular Therapeutix has a market cap or net worth of $2.14B. The enterprise value is $1.29B.

Ocular Therapeutix has 173,995,220 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ocular Therapeutix’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -41.05%.

The current PE Ratio of Ocular Therapeutix is ―. Ocular Therapeutix’s PEG ratio is ―.

In the last 12 months, Ocular Therapeutix had revenue of 63.72M and earned -193.51M in profits. Earnings per share was -1.22.

In the last 12 months, operating cash flow was -175.90M and capital expenditures -3.47M, giving a free cash flow of -179.37M billion.

Ocular Therapeutix pays an annual dividend of ―, resulting in a dividend yield of ―

Ocular Therapeutix upcoming earnings date is Nov 10, 2025, After Close (Confirmed).

Ocular Therapeutix as a current ratio of 10.66, with Debt / Equity ratio of 25.15%

In the past 12 months, Ocular Therapeutix has paid 0.00 in taxes.

Ocular Therapeutix EV to EBITDA ratio is -5.88, with an EV/FCF ratio of -7.61.

Ocular Therapeutix has $391.13M in cash and marketable securities with $76.94M in debt, giving a net cash position of -$314.19M billion.

Gross margin is 89.40%, with operating margin of -269.57%, and net profit margin of -303.67%.

The average price target for Ocular Therapeutix is $17.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy